Immunovia

The Swedish molecular diagnostics firm will use the proceeds, in part, to fund the planned launch of its Immray PanCan-d assay for detecting pancreatic cancer.

Over the next three years, Immunovia and its partners will use the firm's Immray PanCan-d assay to screen 6,000 diabetes patients for pancreatic cancer.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.